title: Effects of twice- versus thrice-weekly electroconvulsive therapy in schizophrenia.
abstract: Electroconvulsive therapy (ECT) has been used to treat a variety of psychiatric disorders since 1938. In clinical practice, a schedule of administration varies greatly and definitive guidelines are not available. The disparity of treatment schedules may influence the rate of response and the duration of morbidity and hospital stay, as well as cognitive adverse effects. The authors conducted a retrospective, comparative study of twice-weekly versus thrice-weekly ECT schedules in ECT-responder schizophrenic patients. Forty-three patients received acute treatment with bilateral ECT and flupenthixol (12-24 mg/d). Outcome measures were the Brief Psychiatric Rating Scale, Global Assessment of Functioning, and the Mini-Mental-State Exam. The thrice-weekly ECT patient group (N = 21) had shorter duration of morbidity and more rapid response than the twice-weekly ECT patient group (N = 22). Twice-weekly ECT treatment is as equally effective as thrice-weekly schedule regarding the degree of improvement. There were no significant differences in the degree of improvement and the cognitive impairment at the end of the study.
authors.affiliation: Department of Psychiatry, Vajira Hospital, Srinakarinwirot University, Bangkok, Thailand.
authors.forename: W
authors.initials: W
authors.lastname: Chanpattana
authors.forename: M L
authors.initials: ML
authors.lastname: Chakrabhand
authors.forename: W
authors.initials: W
authors.lastname: Kitaroonchai
authors.forename: S
authors.initials: S
authors.lastname: Choovanichvong
authors.forename: Y
authors.initials: Y
authors.lastname: Prasertsuk
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004351:Drug Resistance; D004565:Electroconvulsive Therapy / Q000379:methods*; D005260:Female; D005475:Flupenthixol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012559:Schizophrenia / Q000628:therapy*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D005475:Flupenthixol